Collection of Outcomes Data for Pregnant Patients With Cancer
The goal of this research study is to collect information on patients who are or were pregnant while diagnosed with cancer and to store this information in a research database.
|Study Design:||Observational Model: Case-Only|
|Official Title:||Collection of Outcomes Data for Pregnant Patients With Cancer|
- Research database of information on patients who are or were pregnant while diagnosed with cancer. [ Time Frame: 14 Years ] [ Designated as safety issue: No ]
|Study Start Date:||December 2005|
|Estimated Primary Completion Date:||December 2019 (Final data collection date for primary outcome measure)|
Pregnant Patients with Cancer
Patients that are or were pregnant when diagnosed with cancer.
Other: Data Collection
Information about the type of cancer, type of treatment, and details about pregnancy will be collected.
If you agree to take part in this study, information about the type of cancer, the type of treatment you have had or are having, and details about your pregnancy will be collected for the database. Data will be collected from patients seen at MD Anderson since September 2003 until data has been collected for 500 cases. This information will serve as a basis for future studies about pregnant women with cancer. You will receive no special tests or treatment at MD Anderson as a result of this study.
Progress notes and ultrasound reports about your pregnancy will be requested from Maternal Fetal Medicine and/or from your personal obstetrician. This information will be entered into the database and also included in your medical record. If the information is not consistent in the record, we may contact you to clarify the information. You will remain on study until your pregnancy and/or any treatment you are receiving are completed.
Periodically the database will be updated to include information about patient survival. This information is usually found in the medical record however it may be necessary to contact you directly.
This is an investigational study. About 500 patients will take part in this study. All will be enrolled at MD Anderson.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00507572
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Andrea Milbourne, MD||M.D. Anderson Cancer Center|